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Abstract
Background: Pemphigoids are rare diseases associated with IgG, IgE and IgA autoantibodies against collagen XVII/
BP180. An entity of the pemphigoid group is the lamina lucida-type of linear IgA disease (IgA pemphigoid)
characterized by IgA autoantibodies against BP180. While for the detection of IgG and IgE autoantibodies specific
to collagen XVII several ELISA systems have been established, no quantitative immunoassay has been yet
developed for IgA autoantibodies. Therefore, the aim of the present study was to develop an ELISA to detect IgA
autoantibodies against collagen XVII in the sera of patients with pemphigoids.
Methods: We expressed a soluble recombinant form of the co l l a g e nX V I Ie c t o d o m a i ni nm a m m a l i a nc e l l s .
Reactivity of IgA autoantibodies from patients with IgA pemphigoid was assessed by immunofluorescence
microscopy and immunoblot analysis. ELISA test conditions were determined by chessboard titration
experiments. The sensitivity, specificity and the cut-off were determined by receiver-operating characteristics
analysis.
Results: The optimized assay was carried out using sera from patients with IgA pemphigoid (n = 30) and healthy
donors (n = 105). By receiver operating characteristics (ROC) analysis, an area under the curve of 0.993 was
calculated, indicating an excellent discriminatory capacity. Thus, a sensitivity and specificity of 83.3% and 100%,
respectively, was determined for a cut-off point of 0.48. As additional control groups, sera from patients with
bullous pemphigoid (n = 31) and dermatitis herpetiformis (n = 50), a disease associated with IgA autoantibodies
against epidermal transglutaminase, were tested. In 26% of bullous pemphigoid patients, IgA autoantibodies
recognized the ectodomain of collagen XVII. One of 50 (2%) of dermatitis herpetiformis patients sera slightly
topped the cut-off value.
Conclusions: We developed the first ELISA for the specific and sensitive detection of serum IgA autoantibodies
specific to collagen XVII in patients with pemphigoids. This immunoassay should prove a useful tool for clinical and
translational research and should essentially improve the diagnosis and disease monitoring of patients with IgA
pemphigoid. Moreover, our findings strongly suggest that IgA pemphigoid and IgG bullous pemphigoid represent
two ends of the clinical spectrum of an immunological loss of tolerance against components of hemidesmosomes,
which is mediated by both IgG and IgA autoantibodies.
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Pemphigoids are rare autoimmune blistering disorders
associated with autoimmunity against hemidesmosomal
proteins [1]. Main entities of the pemphigoid group include
bullous pemphigoid, pemphigoid gestationis, linear IgA
disease, mucous membrane pemphigoid and lichen planus
pemphigoides with an approximate annual incidence of 7,
0.5, 0.5, 1 and undefined cases in one million, respectively
[2-5]. A major target of pemphigoid autoantibodies is the
bullous pemphigoid antigen of 180 kDa (BP180), also
referred to as collagen XVII, a hemidesmosomal trans-
membrane protein with a type II orientation whose extra-
cellular domain consists of 15 collagenous regions
interrupted by non-collagenous portions (Figure 1A)
[1,4,6]. In a minority of patients, IgA reactivity against
BP230, an intracellular hemidesmosomal component, has
been detected [7]. A hallmark of collagen XVII is its consti-
tutive shedding yielding a shorter and soluble form of the
molecule that spans most of its ectodomain [8,9].
BP180 is targeted by autoantibodies of different Ig iso-
types, including different IgG subclasses, IgA and IgE
[10-13]. The pathogenic relevance of IgG autoantibodies
against BP180 is supported by several lines of evidence:
1) the transplacental transfer of pemphigoid IgG autoan-
tibodies from mothers to the fetus induces transient skin
blistering in the newborn [14-16]; 2) serum levels of IgG
autoantibodies against BP180 correlate with disease activ-
ity in patients with bullous pemphigoid and pemphigoid
gestationis [17-20]; 3) patients autoantibodies against
BP180 recruit leukocytes to the dermal-epidermal junc-
tion and induce dermal-epidermal separation of human
skin [21,22]; 4) IgG antibodies against BP180 induce sub-
epidermal blistering when passively transferred into neo-
natal autoantigen humanized, wild type mice and
hamsters [23-26]; 5) grafting of human BP180 transgenic
mouse skin induces an autoimmune response resulting in
subepidermal blistering in wild-type animals [27,28]. IgE
autoantibodies against BP180 correlate with disease activ-
ity in pemphigoid patients and induce eosinophil infiltra-
tion and dermal-epidermal separation when injected into
human skin grafted on immunodeficient mice [29-31].
While the pathogenic potential of IgG and IgE autoan-
t i b o d i e sa g a i n s tB P 1 8 0w a sc h a r a c t e r i z e dex vivo and in
animal models, the pathogenicity of IgA autoantibodies
was relatively less studied [32]. Very recently, we
demonstrated that IgA autoantibodies from patients
with linear IgA disease induce granulocyte-dependent
dermal-epidermal separation in cryosections of human
skin (van der Steen et al, unpublished).
Linear IgA disease was defined as a new entity different
from dermatitis herpetiformis on the basis of a linear IgA
deposition at the dermal-epidermal junction [33,34].
Further studies revealed heterogeneous molecular specifi-
city of the IgA autoantibodies in patients with linear IgA
disease, including BP180, BP230, collagen VII as well as
still unidentified antigens of 180-, 200-, and 285-kDa [35].
While in most patients, IgA autoantibodies bind to the
epidermal side of the salt-split skin by indirect immuno-
fluorescence (IF) microscopy, staining of the dermal side
of the artificial split may be also detected. IgA autoantibo-
dies from pemphigoid patient sera recognize several forms
of BP180 and preferentially bind to proteolytic products of
this autoantigen [36-38]. Initial studies have shown that a
97 kDa protein (LABD97) is responsible for basement
membrane binding of IgA in patients with linear IgA dis-
ease and that this protein is recognized in human skin
extracts by IgA autoantibodies, when immunoblot analysis
is performed [36]. Further studies have shown that a
120 kDa protein, referred to as linear IgA disease antigen
(LAD)-1, secreted into the supernatants of cultured kerati-
nocytes is also target of linear IgA disease autoantibodies
[37]. Based on antigenic cross-reactivity between LAD-1
Figure 1 Recombinant ectodomain of BP180 used in this study. A: Schematic representation of human BP180 and its ectodomain consisting
of alternating collagenous (C) and non-collagenous (NC) domains. The recombinant form of BP180 ectodomain used for the development of the
current ELISA system spans from aa 490 through aa 1497 and has an NH2-terminal hexahistidine tag. B: Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis of the purified recombinant protein without and with previous boiling, which migrates around 360 (lane 2) and 120 kDa
(lane 3), respectively. C: Immunoblot analysis of the native, normal human keratinocyte-derived shed BP180 ectodomain (lane 1) and the
recombinant BP180 ectodomain (lane 2) using a monoclonal antibody specific to BP180. Weight markers of 116 and 66 kDa are shown to the
left.
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and LAD-1 are fragments of BP180 [38]. Subsequent inde-
pendent studies confirmed that LABD97 and LAD-1
indeed represent portions of the extracellular domain of
BP180 [8,9,39].
For the detection of autoantibodies against BP180,
belonging to different immunoglobulin isotypes, several
ELISA systems have been established. To detect IgG class
autoantibodies from patients’ sera has been the focus of
immunoassays developed until now [19,20,40-43]. Two
of these test systems are commercially available and
widely used in diagnosis. Recently, ELISA systems using
a recombinant form of BP180 NC16A domain were
established for the detection of specific IgE in pemphi-
goid patients [31,44]. In contrast, an ELISA for the detec-
tion of IgA autoantibodies in pemphigoid diseases has
not yet been developed. Both, (i) IgA deposition at the
dermal-epidermal junction being a major diagnostic cri-
terion and (ii) the demonstration of the pathogenic
potential of IgA autoantibodies in patients with linear
IgA disease emphasize the need of elaborating a sensitive
and specific immunoassay to detect the IgA autoantibo-
dies in this orphan disease.
Therefore, in the present work, we used a recombinant
form of the ectodomain of human BP180 to establish an
ELISA for the detection of IgA autoantibodies. Our results
show that ELISA using the ectodomain of BP180 is a sen-
sitive and most specific system for detection of circulating
IgA autoantibodies in patients with pemphigoids.
Materials and methods
Human sera
Serum samples were obtained from patients with linear
IgA disease (n = 30, mean age 56 years), bullous pemphi-
goid (n = 31, mean age 76.5 years), and dermatitis herpeti-
formis (n = 50, mean age 43 years) before initiation of
treatment, as well as from healthy donors (n = 105, mean
age 43 years). Our present study focuses on the IgA pem-
phigoid subgroup of the linear IgA disease patients, char-
acterized by IgA binding to the epidermal side of the salt-
split skin by indirect IF microscopy. Sera from patients
with IgA epidermolysis bullosa acquisita or from patients
with laminin autoimmunity were not included. The clini-
cal diagnosis of IgA pemphigoid was confirmed by (i) sub-
epidermal blisters, (ii) linear IgA deposition along the
dermal-epidermal junction of perilesional skin by direct IF
microscopy, and (iii) circulating IgA autoantibodies bind-
ing to the epidermal side of 1M salt-split skin by indirect
IF microscopy. The clinical diagnosis of bullous pemphi-
goid was validated by (i) subepidermal blisters with inflam-
matory infiltrate, (iii) linear IgG deposition at the
basement membrane zone revealed by direct IF micro-
scopy, and (iii) circulating IgG autoantibodies to the epi-
dermal side of 1M salt-split skin as shown by indirect IF
microscopy and ELISA using a recombinant form of the
16
th non-collagenous region of BP180 expressed as a glu-
tathione-S-transferase fusion protein. Patients with both
IgG and IgA deposition at the dermal-epidermal junction
were diagnosed as bullous pemphigoid. For the experi-
ments conducted, we obtained approval from the Ethics
Committee of the Medical Faculty of the University of
Freiburg, Germany (Institutional Board Projects no 318/07
and 407/08). We obtained informed consent from patients
whose material was used in the study, in adherence to the
Helsinki Principles.
Cell culture
HaCaT human keratinocytes were cultured in serum
free, low calcium KGM medium, supplemented with
KGM Supplement Mix and CaCl2 (all from PromoCell),
as well as L-glutamine, penicillin and streptomycin (all
from Biochrome). Transfected Flp-In HEK 293T cells
(Flp-In™-293, Invitrogen) were cultured in DMEM
medium, without phenol red (Gibco) supplemented with
10% FCS, L-glutamine, penicillin, streptomycin and
hygromycin (all from Biochrome).
Production of recombinant BP180 ectodomain
The ectodomain of BP180, corresponding to amino
acids 490-1497 was produced by stable expression in
Flp-In HEK-293 cells (Invitrogen) as reported [45].
Briefly, the recombinant protein encoding for the ecto-
domain of human BP180 with an N-terminal Ig  chain
signal sequence and hexahistidine tag was affinity puri-
fied from culture medium by metallochelate affinity
using Ni-NTA (Qiagen). Alternatively, the recombinant
protein from harvested culture media was precipitated
with 45% ammonium sulphate followed by dialysis
against PBS. The purified protein’s concentration was
determined by spectrophotometry at 280 nm and this
protein was subsequently used to determine the concen-
tration of the specific protein in the precipitated protein
by densitometric comparison of the specific bands of
the Coomassie stained gel using the ImageJ software
(http://rsb.info.nih.gov/ij).
Enzyme-linked immunosorbent assays
IgG pemphigoid autoantibodies were detected by ELISA
utilizing a recombinant form of the 16
th non-collagenous
region of BP180 expressed as a glutathione-S-transferase
fusion protein following manufacturer’s instructions (MBL
Co, Nagoya, Japan). For detection of IgA autoantibodies,
96-well microtiter plates (Greiner Bio-One, Germany)
were coated with 1.4 μg/well of recombinant BP180 ecto-
domain in 0.1 M bicarbonate buffer (pH 9.6), overnight at
4 °C. After washing with 0.05%Tween20-PBS (w/v) and
subsequent 1 h blocking with 2% BSA-PBS (w/v) the
plates were incubated for 1 h with 1:50 diluted sera in 1%
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detected using a 1000-fold dilution of a horseradish-perox-
idase (HRP) conjugated rabbit anti-human IgA antibody
(ab8510, Abcam) and orthophenylene diamine (Dako). All
steps were carried out at room temperature. The optical
density (OD) was read at 490 nm using an automated
spectrophotometer (Sirius HT-TRF, MWG). Each serum
was tested in duplicate. The cut-off for positivity was vali-
dated and optimized by receiver-operating characteristics
(ROC) analysis as described below and was defined as 0.48
OD units at 490 nm.
In order to rule out the possibility of a nonspecific cross-
reaction between the secondary HRP-labeled anti human
IgA antibody and the IgG autoantibodies in bullous pem-
phigoid patients’ sera we performed the ELISA described
above with sera of known high IgA and IgG titers from
IgA pemphigoid and bullous pemphigoid patients, respec-
tively. Normal human serum was used as control. Bound
IgG and IgA antibodies were detected in all samples with
a 5000-fold diluted, HRP-labeled goat anti-human IgG
antibody (ab6858, Abcam) and the HRP conjugated anti-
human IgA antibody.
IgG autoantibodies against BP230 were detected by the
MESACUP BP230 commercial ELISA kit (MBL Co,
Nagoya, Japan) following the manufacturer’s instructions
[46]. For the detection of IgA autoantibodies against BP230,
we have slightly modified the kit protocol. Briefly, BP230
microwell strips were incubated with 50 times diluted linear
IgA disease patients’ sera and appropriate control sera.
After washing, the bound antibodies were detected using
1000-fold diluted HRP-conjugated anti-human IgA anti-
body (ab8510, Abcam) and the tetramethylbenzidine dihy-
drochloride (TMB)/ hydrogen peroxide substrate solution
from the kit.
SDS-PAGE and immunoblot analysis
Immunoblotting with recombinant or native BP180 ecto-
domain proteins was performed as described with minor
modification [18,47]. Briefly, preparations of recombinant
BP180 ectodomain, native shed BP180 and precipitated
supernatant of empty pcDNA5/FRT transfected HEK-293
cells were separated by SDS-PAGE on 6-8% preparative
gels, under reducing conditions, followed by transfer onto
nitrocellulose (Whatman/Protran BA85). Membrane strips
were incubated overnight with 50-fold diluted serum or
800-fold diluted mouse mAb NC16A-3 directed against
the 16
th non-collagenous domain of BP180. Reactivity was
visualized with secondary, HRP-conjugated rabbit anti-
human IgA (Abcam) or anti-mouse IgG (BioRad) antibo-
dies and diaminobenzidine (Merck).
Indirect immunofluorescence
Detection of circulating autoantibodies by indirect
immunofluorescence followed published protocols
[18,47]. Briefly, frozen sections of salt-split normal
human skin were incubated in a first step with 10-fold
diluted sera from patients with IgA pemphigoid, bullous
pemphigoid and healthy donors and in a second step
with 40-fold diluted, fluorescein isothiocyanate (FITC)
conjugated polyclonal goat anti-human IgA antibody
(Invitrogen).
Statistical analysis
Diagnostic parameters of our new ELISA were opti-
mized by using the ROC analysis. Therefore, to deter-
mine the cut-off value for the ELISA using recombinant
BP180 ectodomain, we performed a ROC analysis by
plotting on the X-axis the 1 - specificity (the false posi-
tive rate) and on the Y-axis the sensitivity (the true posi-
tive rate). The diagnostic sensitivity and specificity are a
function of the selected cut-off value. In the diagnostic
context of pemphigoid diseases, which have a very low
prevalence, it is advisable to choose a cut-off to maxi-
mise the specificity of the assay. In this regard, a specifi-
city of 97.5% or higher may be considered an optimal
target. A similar specificity would be aimed by applying
an alternative method of calculating the cut-off based
on the mean plus two standard deviations (2SD) of the
negative reference sample [48]. Correlations were ana-
lyzed by the Spearman’s rank correlation test. Propor-
tion comparison was examined by Fisher’se x a c tt e s t .
Data are considered significantly different if the p <0.05.
Statistical analyses were performed using the GraphPad
Prism statistical package (v5; GraphPad Software, San
Diego, CA).
Results
Generation of the recombinant autoantigen
When separated by SDS-PAGE without or with previous
boiling, the recombinant protein migrated consistently
with the calculated molecular masses of 360 kDa (Figure
1B, lane 2) and 120 kDa (Figure 1B, lane 3), for its trimeric
and monomeric forms, respectively. This SDS-PAGE
migration pattern matched the one observed for the kerati-
nocyte-derived shed ectodomain of BP180 protein (data
not shown) indicating that the recombinant protein forms
a native-like collagenous trimerized structure. Monoclonal
antibodies specific for the BP180NC16A domain of BP180,
recognized the keratinocyte-derived shed ectodomain
(Figure 1C, lane 1) and the recombinant protein by immu-
noblot analysis (Figure 1C, lane 2).
Immunoreactivity of recombinant BP180 with IgA
autoantibodies
IgA autoantibodies from reference IgA pemphigoid
patients’ sera (n = 5) recognized the recombinant and
the native BP180 ectodomain by immunoblotting. None
of the normal human sera reacted with the autoantigens
Csorba et al. Orphanet Journal of Rare Diseases 2011, 6:31
http://www.ojrd.com/content/6/1/31
Page 4 of 10and IgA antibodies from none of the tested sera bound
to the precipitated proteins of the empty vector trans-
fected HEK cell culture medium. Representative exam-
ples are shown in Figure 2.
Development of ELISA using recombinant BP180
The working conditions, including antigen amount/well,
dilution of sera and secondary antibodies have been
defined by an initial chessboard titration (data not
shown). The secondary HRP-labeled anti-human IgA
antibody was tested by ELISA (see Methods) in order to
rule out nonspecific cross-reactivity with IgG autoanti-
bodies. No cross-reactivity was found (data not shown).
To determine the cut-off value of the newly established
immunoassay, we performed a ROC analysis of the
ELISA readings with sera from 30 IgA pemphigoid
patients and 105 healthy donors as controls. Based on a
calculated specificity of 100% and a sensitivity of 83.3%
the cut-off was set at 0.48 OD reading units (Figure 3).
ELISA using recombinant BP180 is a sensitive and specific
tool to detect IgA autoantibodies in pemphigoid patients
Applying the cut-off value of 0.48 defined by ROC ana-
lysis for the newly developed ELISA showed that 25
(83.3%; 95% CI: 65.2%-94.3%) of IgA pemphigoid and 8
(26.0%; 95% CI: 12.0%-45.0%) of bullous pemphigoid
patients were positive, while 1 (2%; 95% CI: 0.05%-
10.0%) of patients with dermatitis herpetiformis slightly
topped the cut-off value (Figure 4). Serum from none of
the healthy donors (0%; 95% CI: 0.0%-4.0%) showed IgA
reactivity with the recombinant BP180 ectodomain
(Table 1). Therefore, a sensitivity and a specificity of
83.3% (95% CI: 70-97%) and 100% (95% CI: 96-100%),
respectively, were calculated for the ELISA detecting
IgA autoantibodies against BP180 in patients with IgA
pemphigoid. The area under the curve (AUC) was 0.993
(95% CI.: 98.4%-100%). IgA autoantibodies against
BP180 ectodomain were primarily detected in bullous
pemphigoid patients showing IgG reactivity against the
BP180 NC16A region by ELISA (n = 8). IgA autoantibo-
dies against BP180 ectodomain were found in only 1 of
16 bullous pemphigoid (6.25%, 95% CI.: 0%-28%)
patients with negative BP180 NC16A.
Levels of BP230-specific IgA and IgG autoantibody in IgA
pemphigoid patients’ sera
While BP180 is considered the major autoantigen in IgA
pemphigoid, BP230 has been also documented as target
of these autoantibodies. Therefore, we have measured
the IgA and IgG levels agains BP230 by ELISA in our
30 IgA pemphigoid patients’ sera. In 5 patients, we have
detected IgA autoantibodies against BP230, whereas
none of the sera had detectable IgG against BP230
(Table 2).
IgA levels by BP180 ELISA correlate with the IgA
reactivity against the dermal-epidermal junction by IF
microscopy
The indirect IF microscopy on salt-split skin is a stan-
dard diagnostic tool in pemphigoid diseases. To further
characterize the suitability of the newly developed
ELISA for diagnosis of pemphigoid diseases, we corre-
lated in IgA pemphigoid patients the IgA levels by
ELISA with the semi-quantitative reactivity scores by IF
microscopy on salt-split skin. When the IgA levels of
BP180-specific IgA autoantibodies were plotted against
the IgA indirect IF microscopy scores, a positive correla-
tion (r = 0.71; 95% CI: 31-89%; p < 0.005) was obtained
(Figure 5).
Analysis of IgA immunoreactivity against BP180
ectodomain in bullous pemphigoid patients
The reactivity of IgA autoantibodies from sera of bul-
lous pemphigoid patients was analyzed by IF microscopy
using frozen sections of human salt-split skin. Represen-
tative examples are shown in Additional file 1. Thirteen
Figure 2 Immunoreactivity of IgA autoantibodies with native and recombinant BP180 ectodomain. Precipitated, recombinant (lanes 1-6)
and native, keratinocyte-derived (lanes 7-12) BP180 ectodomain immunoblotted with IgA pemphigoid (LAD) patients’ sera (lanes 1-3, 7-9) and
control sera (NHS) (lanes 4, 5, 10 and 11). As substrate control (lanes 13-18), precipitated culture medium from cells transfected with empty
vector was immunoblotted using the same LAD (lanes 13-15) and NHS (lane 16, 17) sera. Presence or absence of the 120 kDa ectodomain was
visualized using a specific monoclonal Ab (lanes 6, 12 and 18).
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tive IgA antibodies binding to the epidermal side of the
split skin. When immunoblot analysis was performed to
identify IgA autoreactivity, we found that 13 and 19 of
31 patients recognized the native and the recombinant
BP180 ectodomain, respectively. Characteristic examples
are depicted in Additional file 1.
Comparison of different immunoassays for the detection
of BP180-specific IgA autoantibodies in pemphigoid
diseases
We compared using Fisher’s exact test the findings in
IgA pemphigoid patients obtained by ELISA using
recombinant BP180 ectodomain and immunoblotting
with native and recombinant LAD-1 antigen. Results are
summarized in Table 2. The calculated p values of 0.703
and 0.502, respectively, show that the ELISA and immu-
noblotting results are not significantly different. Discre-
pancies were observed in only 4 (15%) and 5 (18%)
patients having different results by ELISA compared
with immunoblotting with the native LAD-1 and ELISA
compared with immunoblotting with recombinant
BP180 ectodomain, respectively.
Discussion
Several quantitative immunoassays for the detection of
IgG and IgE autoantibodies against BP180 have already
been established [19,20,31,40-44]. Using these tests, a
plethora of clinical and experimental data have been
generated, which decisively influenced our knowledge
on disease pathogenesis and are firmly implemented in
the diagnosis and monitoring of pemphigoid diseases
[1,49]. In addition to IgG and IgE, IgA autoantibodies
are present to different extent in pemphigoid diseases.
While pemphigoid patients showing a predominant IgA
autoimmune response directed against BP180 are diag-
nosed as linear IgA disease, IgA autoantibodies may
complement a dominant IgG response in bullous pem-
phigoid or mucous membrane pemphigoid [1]. However,
quantitative assays for measuring the levels of serum
IgA autoantibodies in pemphigoid diseases have not
been established yet. Therefore, in the present study, we
Figure 4 ELISA reactivity of linear IgA disease and control sera
with the recombinant BP180 ectodomain. Scatter plots represent
corrected optical density measurements of serum reactivity of IgA
pemphigoid (LAD), dermatitis herpetiformis (DH), bullous
pemphigoid (BP) patients and age matched, healthy donors (NHS)
with the recombinant BP180 ectodomain. The cut-off of the assay is
represented by a dashed line. Numbers in brackets are positive and
total cases, respectively.
Table 1 Sensitivity and specificity of the IgA ELISA with
recombinant BP180 ectodomain
Sera Positive/Total Sensitivity (95% CI) Specificity (95%CI)
LAD 25/30 (83%) 83.3% (65.2%-94.3%) 100% (96.55%-100%)
BP 8/31 (26%) 26% (12.0%-45.0%) 100% (96.55%-100%)
DH 1/50 (2%) 2% (0.05%-10.0%) 100% (96.55%-100%)
NHS 0/105 (0%) 0% (0.0%-4.0%) 100% (96.55%-100%)
Figure 3 Receiver-operating-characteristic (ROC) curve.A U C ,
area under the curve. Test performed with sera from IgA
pemphigoid patients (n = 30) and controls (n = 105).
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detection of IgA autoantibodies.
For detecting the IgA autoantibodies in pemphigoid
diseases we have used a recently generated recombinant
form of the ectodomain of BP180 [45]. The ectodomain
of the autoantigen was expressed in a human cell line to
ensure optimal posttranslational modifications of the
protein, which were shown to influence the binding of
pemphigoid autoantibodies of the IgG class [50]. IgA
reactivity was found by ELISA using a recombinant
form of the 16
th non-collagenous region of BP180,
which was expressed as a glutathione-S-transferase
fusion protein in bacteria, in about 20% of IgA pemphi-
goid patients [51]. The expression of the antigen in
mammalian cells and the fact that our recombinant
form of BP180 contains its entire ectodomain signifi-
cantly raised the sensitivity and specificity of the immu-
noassay and strongly support its use for the detection of
IgA autoantibodies for the diagnosis of pemphigoid
diseases.
The ELISA system developed in the present study was
s h o w nt ob eh i g h l ys e n s i t i v ea n ds p e c i f i cf o rt h e
detection of IgA autoantibodies in IgA pemphigoid.
Since IgA reactivity with the epidermal side of the salt-
split human skin by indirect IF microscopy was an
inclusion criterion of the study patients, a direct com-
parison of the sensitivity of these 2 assays was not possi-
ble in the present work. The observation that IgA
autoantibodies against BP180 were detected in bullous
pemphigoid patients is in line with previous findings
[7,52]. This intriguing finding prompted us to character-
ize the detection of IgA autoantibodies against BP180 by
our ELISA in patients negative for IgG autoantibodies
by the commercially available ELISA using the recombi-
nant 16
th non-collagenous region of BP180 (MBL Co,
Nagoya, Japan). However, only 6.25% of patients nega-
tive for IgG BP180NC16A ELISA showed IgA reactivity
against the BP180 ectodomain. Nevertheless, our find-
ing, that a significant proportion of the bullous pemphi-
goid patients show IgA autoantibodies against the
ectodomain of BP180 suggests that the newly developed
IgA ELISA may be a useful ancillary diagnostic tool in
patients with bullous pemphigoid. In our patient cohort,
only a minority of sera (approximately 16%) showed IgA
reactivity against BP230, confirming that BP180 is the
major autoantigen in IgA pemphigoid.
In addition to facilitating translational research focusing
on the IgA autoimmune response in pemphigoid diseases,
the newly developed ELISA could complement or replace
the traditional semi-quantitative, observer-dependent and
time-consuming IF microscopy on salt-split skin and
immunoblotting using concentrated conditioned superna-
tant of cultured keratinocytes. In contrast to IgG reactivity
[20], the ELISA levels of BP180-specific IgA correlated
well with the IgA reactivity by indirect IF microscopy. In a
recent study, we have investigated the potential of neoepi-
tope-specific rabbit IgG antibodies to induce dermal-
epidermal separation in an ex vivo assay [45]. Our results
showed as proof-of-principle that neoepitope-specific anti-
bodies are pathogenic. However, the pathogenic potential
of neoepitope-specific patient IgA autoantibodies has not
been directly addressed yet. Using the newly developed
ELISA with further recombinant forms of the BP180 ecto-
domain, which may better reproduce the neoepitopes of
Table 2 Immunoreactivity profile of linear IgA disease patients






ELISA BP230-IgA ELISA BP230-IgG
positive negative positive negative positive negative positive negative
ELISA BP180
positive
25 (83%) 20(77%) 3 (11.5%) 20 (71.4%) 4 (14.3%) 4 (13.3%) 21 (70%) 0 (0%) 25 (83%)
ELISA BP180
negative
5 (17%) 1 (3.8%) 2 (7.7%) 1 (3.6%) 3 (10.7%) 1 (3.3%) 4 (13.3%) 0 (0%) 5 (17%)
n = 30 n = 26 n = 28 n = 30 n = 30
n-total number of tested sera.
Figure 5 Correlation of BP180-specific IgA levels by ELISA with
IgA reactivity by IF microscopy in IgA pemphigoid patients.
Spearman rank coefficient (r) = 0.71, 95% confidence interval 31-
89%, p < 0.005, n = 16.
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diagnostic relevance of measuring specifically the neoepi-
tope-specific IgA autoantibodies.
In addition to healthy blood donors, our control group
included patients with dermatitis herpetiformis. Dermatitis
herpetiformis is a polymorphic autoimmune blistering dis-
ease with granular IgA and epidermal transglutaminase
deposition in the papillary dermis, without circulating IgA
autoantibodies binding to the basement membrane or
hemidesmosomes. The disease is associated with a latent
gluten-free enteropathy and the majority of patients have
IgA type epidermal and tissue transglutaminase antibodies
[53,54]. These diseases are associated with IgA autoantibo-
dies staining the endomysium by IF microscopy and
recognizing the tissue and epidermal transglutaminase
[55,56]. Dermatitis herpetiformis shows overlapping clini-
cal and histopathological features with the pemphigoids
[1,53]. In 1979, linear IgA disease was defined as a new
entity different from dermatitis herpetiformis on the basis
of a linear IgA deposition at the dermal-epidermal junc-
tion, which still constitutes its golden diagnostic standard
[33,34]. The characteristic diagnostic IF microscopy tests
in dermatitis herpetiformis and linear IgA disease were
complemented by the development of immunoassays for
detecting IgA autoantibodies specific for tissue and epider-
mal transglutaminase [55-58]. The ELISA system devel-
oped in this study adds a new relevant tool, which further
facilitates the positive and differential diagnosis of linear
IgA disease and dermatitis herpetiformis.
In summary, our results establish an ELISA system for
measuring IgA autoantibodies against BP180 in pemphi-
goid diseases. The newly developed ELISA is the first
molecular quantitative immunoassay important for the
diagnosis of linear IgA disease. In addition, this immu-
noassay should prove a useful tool for clinical research
and could optimize the diagnosis and monitoring of pem-
phigoid diseases. Moreover, our findings strongly suggest
that linear IgA disease and bullous pemphigoid represent
two poles of the clinical spectrum of an immunological
loss of tolerance against defined adhesion proteins of
hemidesmosomes which is associated, with both IgG and
IgA autoantibodies.
Additional material
Additional file 1: Characterization of IgA autoreactivity in bullous
pemphigoid (BP) patients. A-F: Cryosections of human salt split skin
were incubated with BP sera (A, B, D, E), serum from a patient with IgA
pemphigoid (C), and a healthy donor (F). IgA autoantibodies were
detected using a FITC-labeled goat anti-human IgA antibody
(magnification, 200x). G: Keratinocyte-derived shed (lanes 1-5) and
recombinant BP180 ectodomain (lanes 6-10) were separated by 6% SDS-
PAGE and electrophoretically transferred to nitrocellulose. The
membranes were immunoblotted with serum from BP patients (lanes 3-5
and 8-10), a healthy donor (lane 2 and 7) and a BP180-specific mouse
monoclonal Ab (lane 1 and 6), as described in Methods.
Abbreviations
LAD: linear IgA disease; BP: bullous pemphigoid; DH: dermatitis
herpetiformis; NHS: normal human sera.
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